ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript
Hello, and thank you for standing by. Welcome to ACADIA Pharmaceuticals Conference Call. (Operator Instructions) I would now like to hand the conference over to Jessica Tieszen. Ma'am, you may begin.
Thank you. Good afternoon, everyone, and thank you for joining us on today's call to discuss ACADIA's expanded agreement with Neuren Pharmaceuticals. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks before turning it over to Brendan Teehan, our Chief Operating Officer, Head of Commercial, to discuss the debut launch. Mark Schneyer, our Chief Financial Officer, will discuss the financial terms of the Neuren agreement as well as review preliminary second quarter net sales and updated guidance.
Steve will finish our prepared remarks with some closing thoughts before opening the call up for your questions. In addition, Doug Williamson, our Head of R&D; and Kathie Bishop, our Head of Rare Disease and external innovation, will be on the call and available for the Q&A
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |